Related Experiment Video
Updated: Jun 2, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Evaluation of sentinel lymph node biopsy in clinically node-negative breast cancer
Shinya Iida1, Shunsuke Haga, Koji Yamashita
1Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. shinya1s@nms.ac.jp
Summary
Sentinel lymph node biopsy accurately predicts axillary node status in breast cancer patients, reducing morbidity. This study confirms its feasibility and satisfactory results, suggesting it may become a standard surgical technique.
Area of Science:
- Surgical Oncology
- Breast Cancer Management
- Diagnostic Procedures
Background:
- Sentinel lymph nodes (SLNs) are crucial for staging node-negative breast cancer.
- SLN biopsy offers reduced postoperative morbidity compared to axillary lymph node dissection.
- Accurate SLN status guides adjuvant treatment decisions.
Purpose of the Study:
- To analyze the validity and feasibility of the sentinel node biopsy (SNB) procedure.
- To evaluate the identification rate, accuracy, and recurrence rates of SNB.
- To compare SNB outcomes with established clinical trial results.
Main Methods:
- Dual-agent injection (blue dye and radioactive colloid) for SLN identification.
- Analysis of 258 breasts from 253 clinically node-negative breast cancer patients.
- Intraoperative diagnosis for axillary lymph node dissection (ALND) decision.
Main Results:
- High SLN identification rate (99.2%) and accuracy (98.0%).
- Low provisional false-negative rate (7.7%) and axillary recurrence rate (0.4% over 24 months).
- No significant morbidity observed in patients undergoing SNB without ALND.
Conclusions:
- The SNB procedure demonstrated satisfactory and feasible results.
- SNB efficacy and safety align with previous clinical trial findings.
- SNB is poised to become a standard surgical technique for node-negative breast cancer.
